Sterile Oncology Injectable Market 2018 Scope of Current and Future Industry 2028

The global sterile oncology injectable market is projected witness significant growth over the forecast period due to rising prevalence of cancer globally.

Increase in investment by drug manufactures in the development of sterile oncology injectable, short time frame for approval of new drug in cancer treatment are some of the key factor boosting demand for sterile oncology injectable market globally.

For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-6604

Rapid FDA approvals of sterile oncology injectable along with shortened approval times for drug development in cancer care is helping manufacturers to accelerate drug supplies. These factors are eventually boosting the growth of the global sterile oncology injectable market. However, stringent rules and regulations in manufacture of sterile oncology injectable and high quality and care required in manufacturing, challenges in storage, packaging and distribution of oncological sterile injectable are likely to hamper the growth of sterile oncology injectable market. Also, sterile drugs require complex equipment for manufacturing.

Market Expansion Due to Agreements and Partnerships

Sterile oncology injectable manufacturers are focusing on partnership and geographical expansion in different countries to establish facilities in various regions. Pfizer has expanded its oncology portfolio with acquisition of Hospira.

Hospira has a broad sterile injectable product line, which includes acute care and oncology injectable. Baxter also acquired India-based injectable firm Claris Injectable Limited and expanded its portfolio in anti-infective, analgesics and critical care and oncology injectable.

Regional Market Outlook

North America will continue to dominate the global market due to the availability of advanced technologies and more number of clinical trial, surge in demand for innovative medical technology in the U.S. According to the National Institute of Cancer in 2016, around 1,685,210 new cancer cases are likely to be diagnosed in the U.S. Europe is expected to hold second large market share in global sterile oncology injectable market due to growing prevalence of chronic diseases. Competition from low-cost pharmaceutical manufacturing countries such as India and China has led to discontinuation of many products. Asia Pacific is expected to exhibit attractive market share owing to increase in health awareness and demand for advanced medical technology in oncology treatment and increasing investments on low-cost pharmaceutical manufacturing.

Competition Outlook

Examples of some of the key players identified in the global sterile oncology injectable market are Eli Lilly & Company, Biocon Ltd, Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceuticals Industries Ltd, and Pfizer Inc., among others. Sterile oncology injectable are used for cancer treatment and therapies. Recent M&A activities have fueled the growth prospect for sterile oncology injectable. Recent deal of US$ 17 Billion between Pfizer & Hospira provides platform for growth for Pfizer’s Global Established Pharmaceutical (GEP) business. Hospira’s generic sterile injectable products, including acute care and oncology injectable have provided boost to Pfizer’s sterile injectable offerings in oncology market. However, preference of large molecules offers a global opportunity to its manufacturers, as these are the common molecules recently used globally for oncology application.

Sterile CMOs:

• Catalent Pharma Solutions
• Baxter
• Akorn
• Althea
• Vetter
• Piramal Pharma Solutions (ColdStream Laboratories)
• IDT Biologica.

Medium Scale Manufacturers/Providers:

• Biocon Ltd
• Baxter International Inc.
• Hikma Pharmaceuticals PLC
• Sandoz International GmbH

Large Scale Manufacturers/Providers:

• Mylan N.V
• Teva Pharmaceuticals Industries Ltd
• Pfizer Inc.
• Eli Lilly & Company

Key Data Points Covered in Report

The report covers exhaustive analysis on:

• Sterile Oncology Injectable Market by molecule type, distribution channel, indication and region
• Regional level market analysis of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding China & Japan, China, Japan, Middle East & Africa by molecule type, distribution channel, indication segments and country
• Sterile Oncology Injectable Market Dynamics & Opportunity Assessment
• Historical Actual Market Size, 2013 – 2017
• Sterile Oncology Injectable Market Size & Forecast 2018-2028
• Sterile Oncology Injectable Market Current Trends/Issues/Challenges
• Competition & Companies involved

?Research Methodology

The market sizing of sterile oncology injectable will be done by adoption data triangulation approach. Demand side approach will be followed to assess the actual market size of sterile oncology injectable. Secondary research will be performed at the initial phase to identify the Age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information will be eventually analyzed during the entire research project, which helps build a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate. Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analyzed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

By Molecule Type